(TheNewswire)
Vancouver, British Columbia / TheNewswire /
September 19th, 2018 –
BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr.
Paramjit Tappia to its scientific advisory team.
Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Tappia into our scientific advisory
team. His achievements in scientific and clinical research space will be a major asset to BioMark. Dr. Tappia’s expertise in
regulatory and clinical research brings depth and practicality as we begin to commercialize and position our technology for
different oncology applications and potential linkages with other leading global institutions.”
“Biological markers are urgently needed to improve early detection, diagnosis and measuring response to treatment for
cancers at large. BioMark’s technology platform could be a critically important tool for clinicians and the medical institutions”,
says Dr. Tappia.
About Dr. Paramjit Tappia
Dr. Tappia over 30 years of research, including clinical and regulatory experience in clinical research
with focus on nutrition in health and disease, developing novel biomarkers for human disease and understanding of subcellular
and molecular mechanisms of different pathophysiological conditions. He is currently the Principal
Investigator and Clinical Scientist at Asper Clinical Research Institute, St. Boniface Hospital where he manages and
facilitates clinical studies for major corporations. Dr. Tappia holds Ph.D. in Biochemistry from
University of Wolverhampton, U.K. and has published over 100 peer-reviewed articles in leading journals and 26 book chapter
contributions. Dr. Tappia is regularly invited to present at national and international conferences. He
is also actively involved in various community services across the province of Manitoba.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect,
monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to
treatment and potentially for serial monitoring for cancer survivors.
Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation,
concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by
the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking
information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can
give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the
date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether
as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.
Copyright (c) 2018 TheNewswire - All rights reserved.